SCHEMBL4617985

SCHEMBL4617985

O=C(O)CCNS(=O)(=O)c1ccc(-c2cc(-c3ccc(-c4ccccc4)c(C(F)(F)F)c3)on2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 7/20 0.45
PTGS2 P35354 2/20 0.44
MMP2 P08253 2/20 0.44
MMP9 P14780 1/20 0.44
S1PR3 Q99500 3/20 0.44
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PDE10A Q9Y233 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C19 P33261 1/20 0.42
MMP3 P08254 1/20 0.41
HDAC4 P56524 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
IDH2 P48735 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923643 0.93 PTGS2 (0.45) S1PR1PTGS2MMP2MMP9S1PR3
SCHEMBL3091280 0.85 S1PR1 (0.53) S1PR1MMP2MMP9S1PR3HDAC4
SCHEMBL4926895 0.82 ADAMTS4 (0.52) S1PR1PTGS2MMP2MMP9S1PR3
SCHEMBL4934557 0.82 ADAMTS4 (0.52) S1PR1PTGS2MMP2MMP9S1PR3
SCHEMBL4617982 0.82 ADAMTS4 (0.52) S1PR1PTGS2MMP2MMP9S1PR3
SCHEMBL4617666 0.81 PTGS2 (0.54) S1PR1PTGS2MMP2S1PR3CYP1A2
SCHEMBL4929185 0.80 S1PR1 (0.45) S1PR1MMP2S1PR3KDM4EALDH1A1
SCHEMBL4929190 0.80 S1PR1 (0.45) S1PR1MMP2S1PR3KDM4EALDH1A1
SCHEMBL3089144 0.77 S1PR1 (0.50) S1PR1S1PR3MAPTHDAC4HDAC6
SCHEMBL4619710 0.77 S1PR1 (0.49) S1PR1S1PR3CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands NOVARTIS AG (CH) 2008-12-11 US disclosed
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands NOVARTIS AG (CH) 2008-12-11 US disclosed
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands NOVARTIS AG (CH) 2008-12-11 US disclosed
EP-1893591-A1 POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS Novartis AG (CH) 2008-03-05 EP disclosed
WO-2006131336-A1 POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS NOVARTIS AG (CH) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands SOX18, SIGMAR1, SUCNR1 S1PR1 13/4885PTGS2 1915/4885MMP2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.